JW Life Science Completes Product Approval for Nutritional Infusion 'WinnerF A Plus'

Comprehensive Nutritional Infusion with Enhanced Amino Acid Content

JW Life Science announced on the 20th that it has received product approval from the Ministry of Food and Drug Safety for the 'WinnerF A Plus' lineup of total parenteral nutrition (TPN) solutions with increased amino acid content.

JW Life Science Dangjin Production Complex. [Photo by JW Life Science]

WinnerF A Plus is a product with an increased total amino acid content per 1ℓ of mixed solution compared to JW Life Science's total parenteral nutrition solution 'WinnerF.'

Following the central venous 'WinnerF A Plus Injection' in June, JW Life Science obtained product approval from the Ministry of Food and Drug Safety for the entire lineup, including the peripheral venous 'WinnerF A Plus Peri Injection' at the end of August. This is the first time a domestic pharmaceutical company has received approval for a high-amino acid total parenteral nutrition solution.

WinnerF is a total parenteral nutrition solution developed and produced by JW Life Science. One container is divided into three chambers to mix nutrients such as four types of lipids including omega-3 fatty acids, amino acids, and glucose for use. Since its launch in 2013, it has maintained the number one position in the domestic total parenteral nutrition market and has been exported to the European market since 2019.

JW Life Science plans to complete the insurance price listing process for WinnerF A Plus and launch the product by the end of this year. Domestic sales will be handled by JW Pharmaceutical.

A JW Life Science official stated, "Total parenteral nutrition solutions are evolving from an auxiliary concept of 'nutritional supplementation' to therapeutics that help patients recover quickly," adding, "We will continue to lead the domestic and international TPN markets through product development reflecting market needs for patient-tailored total parenteral nutrition solutions."

Meanwhile, in October last year, JW Life Science completed the expansion of TPN Line 3, the country's first fully automated total parenteral nutrition production facility, at its infusion solution manufacturing plant located in Dangjin, Chungcheongnam-do. With the full operation of TPN Line 3, JW Life Science's maximum annual production capacity of total parenteral nutrition solutions increased by 37%, from 10.2 million units to 14 million units. The maximum annual production capacity of all infusion solutions, including total parenteral nutrition solutions, is 180 million units, the largest scale in the country.